The CD4/CD8 ratio of infused CD19‐CAR‐T is a prognostic factor for efficacy and toxicity
British Journal of Haematology · 2023-11 · 203 (4) · 564-570
DOI: 10.1111/bjh.19117 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 03.10.2023. Verfasst von Eugenio Galli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 71-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
CD4 + and CD8 + chimeric antigen receptor T cells (CAR‐T) play different roles in the in vivo anti‐tumour response, but the role of the CD4 + /CD8 + ratio among infused CAR‐T has not been clearly defined yet. We analysed leftovers from infused anti‐CD19 CAR‐T bags of 31 patients with aggressive B‐cell lymphomas. The median ratio was 1.44, lower for brexu‐cel compared to tisa‐cel and axi‐cel. The CAR+CD4 + /CD8 + ratio was influenced by lactate dehydrogenase levels at apheresis, not by age, previous treatments or the CD4 + /CD8 + ratio in peripheral blood. Patients with a response at 3 months after CAR‐T (M3) had a lower CAR+CD4 + /CD8 + ratio in the infused products compared to non‐responders (ratio 0.74 vs. 2.47, p = 0.011). A CAR+CD4 + /CD8 + ratio higher than the cut point of 1.12 was associated with an increased risk of treatment failure at M3 (OR 23.3, p = 0.012) and M6 (OR 10, p = 0.028). The median 6‐month PFS was 76% for patients with a ratio lower than 1.12% vs. 31% for the others. The prognostic role of the CAR+CD4 + /CD8 + ratio was independent of the costimulatory domain (CD28 vs. 4‐1BB) of the product (OR 16.41, p = 0.041). Our data indicate a crucial role for CD8 + CAR‐T and the CAR+CD4 + /CD8 + ratio in predicting CAR‐T efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
ORCID-Profile: Eugenio Galli, Silvia Bellesi, Rosalia Malafronte, Elena Maiolo, Patrizia Chiusolo, Simona Sica, Federica Sorà, Stefan Hohaus
Zitieren
APA
Galli, E., Bellesi, S., Pansini, I., Di Cesare, G., Iacovelli, C., Malafronte, R., Maiolo, E., Chiusolo, P., Sica, S., Sorà, F., & Hohaus, S. (2023). The CD4/CD8 ratio of infused CD19‐CAR‐T is a prognostic factor for efficacy and toxicity. British Journal of Haematology, 203(4), 564-570. https://doi.org/10.1111/bjh.19117
Vancouver
Galli E, Bellesi S, Pansini I, Di Cesare G, Iacovelli C, Malafronte R, et al. The CD4/CD8 ratio of infused CD19‐CAR‐T is a prognostic factor for efficacy and toxicity. British Journal of Haematology. 2023;203(4):564-570. doi:10.1111/bjh.19117
BibTeX
@article{Galli2023,
author = {Galli, Eugenio and Bellesi, Silvia and Pansini, Ilaria and Di Cesare, Giacomo and Iacovelli, Camilla and Malafronte, Rosalia and Maiolo, Elena and Chiusolo, Patrizia and Sica, Simona and Sorà, Federica and Hohaus, Stefan},
title = {The CD4/CD8 ratio of infused CD19‐CAR‐T is a prognostic factor for efficacy and toxicity},
journal = {British Journal of Haematology},
year = {2023},
volume = {203},
number = {4},
pages = {564--570},
doi = {10.1111/bjh.19117}
}
EUVIMED